FMI’s New Report, titled, “Pulmonary Arterial Hypertension Treatment Market: Global Industry Analysis and Opportunity Assessment 2016-2026” offers 10-year forecast and analysis.

Valley Cottage, NY -- (SBWire) -- 06/02/2016 --According to World Health Organization (WHO), raised blood pressure is estimated to cause 7.5 million deaths around the world. Hypertension is a risk factor for coronary heart disease, ischemic and hemorrhagic stroke. In addition complications of hypertension includes peripheral vascular disease, heart failure, renal impairment, retinal hemorrhage and visual impairment.

Having family history of Pulmonary Arterial Hypertension, change in life style, unhealthy food, and physical inactivity causes hypertension.

To treat pulmonary atrial hypertension following treatments are available

Medication
Surgeries

Medications include blood vessel dilators (vasodilators), Endothelin receptor antagonists, phosphodiesterase III inhibitors, calcium channel blockers, anticoagulants, diuretics.

Atrial septostomy and Transplantation are the two surgery option for patients who suffering from severe pulmonary atrial hypertension. Transplantation is may be an option for younger people who are suffering from idiopathic pulmonary hypertension.

Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1218

Pulmonary Arterial Hypertension Treatment Market: Drivers and Restraints

According to World Health Organization, Globally the prevalence rate of hypertension was 40% in adults who aged 25 and above in the year 2008. The prevalence rate is high in Africa region and Americas having less prevalence rate in hypertension. Change in the life style, family history of pulmonary atrial hypertension, unhealthy food, and physical inactivity are the risk factors for hypertension as well as drivers for this market. Raising the geriatric population around the world also driver for pulmonary atrial hypertension treatment market. Guidelines form government organizations such as World Health Organization (WHO), Center for Disease Control and Prevention plays a major role in the prevention of pulmonary atrial hypertension treatment.

Pulmonary Arterial Hypertension Treatment Market: Segmentation

Pulmonary Arterial Hypertension Treatment Market is segmented into following types:

Based on Treatment
Medication
Blood Vessel Dilators (Vasodilators)
Endothelin Receptor Antagonists
Phosphodiesterase III Inhibitors
Calcium Channel Blockers
Anticoagulants
Diuretics

Based on End User
Hospital
Drug store
Hospital Pharmacies

Pulmonary Arterial Hypertension Treatment Market: Overview

With good awareness about healthcare among people and guidance from international organizations about the Pulmonary Arterial Hypertension Treatment, the market is expected to have a healthy growth in the forecast period (2016-2026)

Pulmonary Arterial Hypertension TreatmentMarket: Region- wise Outlook

Depending on geographic regions, the global Pulmonary Arterial Hypertension Treatment market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific excluding Japan, Japan and Middle East & Africa.

Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1218

Pulmonary Arterial Hypertension Treatment is high in North America because it is highly developed region, having good healthcare setup and people are having good awareness about health care. Asia Pacific is expected to grow at a remarkable CAGR. Europe also having good growth in this market.

Pulmonary Arterial Hypertension TreatmentMarket: Key Players

Some of the key players in this market are

Pfizer inc.
Bristol myers co
Novartis AG.
GlaxoSmithKline Pharmaceuticals Limited
Baxter
Dr. Reddy's Laboratories Ltd.